Literature DB >> 19908183

Radiofrequency ablation of liver metastases from cancer of unknown primary site.

Sophia Mylona1, Evangelia Stroumpouli, Maria Pomoni, Panagiota Galani, Sparti Ntai, Loukas Thanos.   

Abstract

PURPOSE: This retrospective study was performed to review the efficacy of local radiofrequency ablation (RFA) in all the management of liver cancer of unknown primary site (CUP), and to identify possible prognostic features and complications that affect the efficacy of this treatment on survival.
MATERIALS AND METHODS: From April 2003 to December 2007, 22 patients (15 men, 7 women) with a total of 36 liver metastasis of CUP and poor response to prior systemic chemotherapy were treated with computed tomography-guided RFA. The median age of patients was 66 years. All patients (22/22) had 1-, 3-, and 6- month follow-up and 8/22 of them had a 12-month followup.
RESULTS: The overall median survival of all 22 patients was 10.9 months. Survival was better in patients with lesions 3 cm or smaller. No severe complications, including local seeding, were occured.
CONCLUSION: Our study revealed that RFA appears to be an effective, safe and relatively simple alternative procedure for the local ablation of these lesions. These results are more encouraging for lesions 3 cm or smaller, all of which were successfully treated, as proved by the imaging criteria and the statistical analysis. Further prospective trials are needed to determine whether RFA should be proposed for standard protocols.

Entities:  

Mesh:

Year:  2009        PMID: 19908183     DOI: 10.4261/1305-3825.DIR.1714-08.1

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  4 in total

1.  Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients.

Authors:  Efnan Algin; Ahmet Ozet; Ozge Gumusay; Guldal Yilmaz; Suleyman Buyukberber; Ugur Coskun; Meltem Baykara; Bulent Cetin; Ramazan Yıldız; Mustafa Benekli
Journal:  Wien Klin Wochenschr       Date:  2015-09-15       Impact factor: 1.704

Review 2.  Interventional therapies of unresectable liver metastases.

Authors:  Jun Qian
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-11       Impact factor: 4.553

3.  Nanotechnology for cancer treatment.

Authors:  William H Gmeiner; Supratim Ghosh
Journal:  Nanotechnol Rev       Date:  2015-04       Impact factor: 7.848

4.  Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.

Authors:  Matias Riihimäki; Hauke Thomsen; Akseli Hemminki; Kristina Sundquist; Kari Hemminki
Journal:  BMC Cancer       Date:  2013-01-28       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.